Effective November 1, Rosalind Wright, MD, MPH assumed the dual leadership roles of Dean of Translational Biomedical Research and Director of the Clinical and Translational Science Award (CTSA) at the Icahn School of Medicine at Mount Sinai.
As Dean for Translational Biomedical Research, Dr. Wright provides leadership for clinical and population-based research across the Mount Sinai Health System, applying her expertise and vast experience to supporting and growing our research endeavors. This role dovetails with her directorship of the CTSA, recently re-funded by the NIH to foster high-quality translational research, research education, and the development of innovative resources. Through Mount Sinai’s Conduits program, the CTSA spurs collaborations among clinicians, patients, and scientists, and builds partnerships across a national network of CTSA programs.
“As technological advances and evolving insights into disease causation and individual variation increase the complexity of research and its translation into clinical practice, we are challenged with moving forward integrated team science that informs what genes, environment and life stage mean to defining normal variations and altered health trajectories throughout the life course and across generations,” said Dr. Wright of her new roles. “This is an exciting time for science and medicine with Mount Sinai continuing to lead the way.”
Dr. Wright is a Professor in the Departments of Pediatrics and Preventive Medicine. As a pulmonologist and life course epidemiologist, she has special expertise in prenatal and early childhood factors contributing to the programming of chronic diseases. She has built a large National Institutes of Health (NIH)-funded research program focused on understanding the role of both chemical and non-chemical social stressors in perinatal programming of conditions such as asthma, obesity, cardiometabolic disorders, and neurodevelopment, particularly as they relate to health disparities in socioeconomically challenged urban populations. Dr. Wright’s pioneering research on the role of social factors and toxic stress on disease programming starting in pregnancy was recently recognized through her election as a fellow to the National Academy of Behavioral Medicine Research.
As we welcome Dr. Wright, we want to thank Hugh Sampson, MD, who is scaling back his administrative positions at Mount Sinai to assume a role as Chief Scientific Officer for DVB Technologies, a company that is developing treatments for pediatric food allergies. We wish him well in his new external position and, at the same time, are pleased that he will continue to be a visible, vibrant presence in the Icahn School of Medicine research community.
In a continued effort to support the clinical research community, the Program for the Protection of Human Subjects (PPHS) is offering researchers an opportunity to use Ideate now for Initial (new) Expedited project submissions to the IRB.
Ideate is an advanced, logic-driven, user-friendly system that is specifically designed to simplify and expedite the research application submission process for investigators and research personnel.
Please contact Lori Jennex (firstname.lastname@example.org) directly to discuss this opportunity.
Did you know that the National Institutes of Health (NIH) offers Administrative Supplements to Enhance Diversity, a.k.a. “Diversity Supplements,” which are available for most NIH funded grants with at least two years remaining on their parent grant? These supplements offer the full direct cost rate of 69.5%, if on campus. Interested?
1. You may be eligible, if you are
- A financially disadvantaged high school or undergraduate student,
- Someone with disabilities, or
- Someone who belongs to one or more racial or ethnic minority groups.
2. Applicants may be
- Junior faculty,
- Graduate students,
- Medical students taking off from medical school for a “research year,” or
- High school or college students seeking research experience.
3. Applicants may not be currently supported by the NIH.
The ISMMS currently has 14 funded diversity supplements. However, a recent institutional review indicates that around 70 NIH funded grants qualify for “diversity supplements.” At a greater than 90% funding success rate that means we are essentially “leaving money on the table!”
Support is Available
The Diversity in Biomedical Research Council (DBRC) and the Grants and Contracts Office (GCO) have developed a website http://icahn.mssm.edu/about-us/diversity/diversity-in-biomedical-research-council/diversity-supplements-and-faqs to assist researchers in applying for supplements, which includes templates from successful grants, contact information for current grant awardees, and frequently asked questions (FAQ), all focused on making the application process simpler.
If you know of a promising individual that could qualify for one of these supplements, which include support for compensation and supplies, we encourage you to seek out this funding.
If you have specific questions about applying for a “Diversity Supplement” please contact Elizabeth Urbanski of the Dean’s Office at email@example.com or Allison Gottlieb of the GCO at firstname.lastname@example.org.
As you may have heard, the ISMMS COREs are excited to introduce iLab’s Core Facility Management software, an online system to improve your user experience and simplify the process of ordering and billing for core service requests. The new iLab solution will replace eRAP and move the COREs into the next generation of resource management processes.
Specific benefits of implementing the iLab solution to the PI/user are:
- Researchers can find all shared resource facilities in one central location.
- iLab provides a consistent interface for searching resources, requesting services, and updating project progress.
- CORE landing pages can be viewed external to the system, allowing researchers external to the institution to view services available.
- COREs can automatically generate recharges and invoices. Charges related to core services can be posted directly to the general ledger, eliminating data re-entry, and improving data accuracy.
Additionally, ISMMS is working with iLab to integrate with:
- Our Single Sign On (SSO) system so that users can use their ISMMS login credentials to access iLab (the same credentials used to access ISMMS email).
- Our financial systems so that iLab can house active funds for all PIs and their lab members.
The roll-out, effective 2/1/2016, involves six (6) CORE facilities:
- Biorepository and Research Pathology
- Flow Cytometry
- Human Immune Monitoring
- Mouse Genetics
Please stay tuned for additional announcements as we prepare for this exciting new era in Core Resource Management.
Mount Sinai Innovation Partners, MSIP, is a business unit of the health system that facilitates the real-world application and commercialization of Mount Sinai discoveries and the development of research partnerships. MSIP recently launched new resources on their website, www.ip.mountsinai.org, for faculty, staff and trainees of the health system, including:
- Find Your Representative: a new tool for faculty to quickly find their MSIP business development contact including contact information and a photo.
- Inventors Guide: an updated version of the Inventors Guide is now available. The guide provides an in-depth analysis of technology development and commercialization at the Mount Sinai Health System and engaging with Mount Sinai Innovation Partners.
- Drug Discovery Guide: a new guide for researchers interested in drug discovery and development. This resource document will be presented at an Intellectual Property & Commercialization Speaker Series event in the beginning of 2016, please be on the lookout for more details.
- IP Video Tutorials: learn more about the essentials of technology protection, development and commercialization with this video series from our colleagues at the University of Michigan.
The Department of Corporate and Foundation Relations, part of the Development Office of the Mount Sinai Health System, establishes and stewards institutional relationships with private independent foundations and corporations. Within the framework of the Mount Sinai strategic plan, they work with faculty to develop philanthropic support from these donors.
Their team identifies programs and faculty at Mount Sinai that best fit the philanthropic programs of foundations and corporations, with a focus on Mount Sinai’s strategic priorities. They assist faculty with
- Editing and composing letters of inquiry and proposals,
- Assembling necessary supporting materials,
- Interacting with foundations and corporate prospects,
- Arranging for appropriate institutional signatures on proposals and gift agreements, and
- Compiling required narrative and financial reports.
- They also arrange for site visits and meetings with these donors.
The corporate and foundation relations team partners with the Grants and Contracts Office (GCO), the Committee on Special Awards (CoSA), and Mount Sinai Innovation Partners (MSIP). Working with Development does not change requirements to any of these departments; for example, it does not change requirements involving indirect costs, the rate of fringe benefits, or whether a proposal needs to be submitted to GCO or CoSA.
If you are interested in working with them, or have any questions, please contact the team at CorpFoundHelp@mountsinai.org.
The PPHS and the IRB offices at the Mount Sinai Health System sites have been successfully integrating policies, practices, and forms this year. Below are some key policies and processes that have been adopted by all sites:
- Consent process, policies, and template:
- In April 2015, a system-wide consent template was introduced and became mandatory throughout the system on May 1, 2015. All informed consent documents should be on the 4/1/15 template version.
- In October, 2015:
- The HIV in Research Consent must be used when HIV testing will occur within the research setting, including as part of screening for a research study.
- Consent documents for storing data/specimens will use the same future use language boilerplate.
- Consent documents when depositing data/specimens in large repositories will use the same boilerplate language. (See Guidance on Future Use and GWAS)
- In August, 2015:
- all sites adopted the ISMMS/MSH Phone consent process for minimal risk research when collecting PHI.
- Short Form Consent Policy. In August, all sites adopted the ISMMS/MSH Short Form Consent Policy. All requests must be made in advance to IRB@mssm.edu. Each request is evaluated on a case-by-case basis. (It is rare that a fully translated consent document is not required; ad hoc translation is not allowed).
- Policy on use of external IRBs. In July, all sites agreed to allow for the use of commercial IRBs. These remain limited to specific types of projects and are evaluated on a case-by-case basis. All requests to use a commercial IRB must be sent to IRB@mssm.edu using HRP-229A. There is a one-time administrative set up fee of $575 for industry sponsored research permitted to use a commercial IRB for the official IRB review of the study. For additional information, please review the Use of Commercial IRBs under Guidelines and Policies
- Guidance documents:
- Recruitment methods (revised 10/7/15)
- Screening guidance
As always, we appreciate all you do to protect the research volunteers who agree to take part in the research conducted by Investigators working within the Mount Sinai Health System.